Page 3 - விஸ்கான்சின் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theralase Technologies Inc.: Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study Theralase or the TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ( PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison ( UWH ) has received site Institutional Review Board ( IRB ) approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer ( NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin( Study II ).

Kyle richardKristina hacheyWilliams middletonShawn shiraziCalmette guerinCollege of health sciences university wisconsinUniversity of wisconsin hospitalsTechnologies incDepartment of urologyVenture exchangeUniversity of wisconsin healthRegulation services providerPhoto dynamic compoundsWisconsin health madisonInstitutional review boardMuscle invasive bladder cancer